#China #Suzhou #Ribo Life Science #siRNA Technology #RiboPepSTAR

Ribo Expands Its Reach Beyond the Liver with RiboPepSTAR™ Technology

Suzhou Ribo Life Science Co., Ltd. has recently introduced a pioneering technology called RiboPepSTAR™, which enables targeted delivery of small interfering RNA (siRNA) to various organs beyond just the liver. This innovative method was showcased at the RNA Leaders Europe conference held in Vienna, Austria, on March 19, 2026. The company, listed on the Hong Kong Stock Exchange under the code 6938, is making waves in the biomedical field with its technological advancements.

Following the remarkable success of its earlier solution, RiboGalSTAR™, which supported seven clinical programs and global partnerships valued at over $6 billion, Ribo is broadening its horizons. The RiboPepSTAR™ platform facilitates precise targeting of key organs, offering promising preclinical data across diverse tissues. This development marks a significant step forward in siRNA-based therapies, which are crucial for treating various conditions.

Targeting the Kidneys

Utilizing RiboPepSTAR™, preclinical studies have demonstrated significant uptake in proximal tubular cells across diverse animal models. Notably, there has been an impressive reduction of up to 80% in target gene expression, validated across species from rodents to non-human primates. Physiological proof-of-concept has been established in several disease models, including a type 2 diabetes model that revealed substantial decreases in kidney-related biomarkers. Ribo has successfully transitioned its first kidney-targeted drug into the IND phase.

Focus on the Heart

In addition to targeting kidney function, RiboPepSTAR™ has shown efficacy in cardiac applications. A conjugate specifically designed for the heart demonstrated sustained suppression of gene expression in cardiac models. Minimal effects were noted in other tissues, including muscle, liver, and kidneys, showcasing strong cardiac specificity that is critical for the development of heart disease treatments.

Targeting Adipose Tissue

Furthermore, Ribo's technology displayed its capability in targeting adipose tissue effectively. In studies involving non-human primates, the targeted delivery led to a remarkable 96% gene suppression in fat tissues. This level of precision highlights the platform’s potential in addressing metabolic disorders, thereby expanding the therapeutic applications of siRNA.

Multi-Target Capability

In parallel to these advances, Ribo is also advancing a multi-target siRNA platform which allows a single molecule to silence two or more genes simultaneously. Ribo's dual-target siRNAs achieve gene silencing levels comparable to single-target molecules, facilitating synergistic modulation of metabolic pathways for enhanced therapeutic benefits with a single therapeutic entity.

Collectively, the platforms offered by Ribo, both extrahepatic and multi-target, pave the way for cutting-edge therapies across a multitude of pathological areas. This development aligns with Ribo's commitment to delivering state-of-the-art siRNA medicines to patients globally.

Through the RiboPepSTAR™ technology, Ribo is not just expanding its reach but is fundamentally altering the landscape of therapeutic possibilities, potentially transforming how we treat diseases related to the kidneys, heart, and metabolic systems.